The abstract is read at the publisher; the summary is JClub's.
AAV-HITI with optimized donor DNA enables mutation-agnostic, RHO-specific targeted integration that significantly improves retinal structure, function, and visual acuity in a humanized RP4 mouse model up to 1 year.
- Why it matters: Autosomal dominant RP4 from RHO mutations often acts via gain-of-function or dominant-negative mechanisms, making simple gene supplementation inadequate and requiring mutant allele inactivation.
- What they did: The study used an adeno-associated viral vector homology-independent targeted integration strategy with optimized donor DNA to drive transgene expression from the endogenous RHO locus, then assessed on-target editing in mouse retina and off-target editing in a human cell line.
- The result: In the humanized RP4 model carrying the RHO P23H mutant allele plus an endogenous wild-type mouse Rho allele, treatment significantly improved retinal outcomes through 1 year and supported a human-centric AAV-HITI platform for RP4 evaluation.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.